EDAP TMS Appoints Ken Mobeck CFO, Francois Dietsch CAO

TL;DR

**EDAP just hired a new CFO and CAO, signaling a focus on US growth and shareholder value.**

AI Summary

EDAP TMS SA, a global leader in robotic energy-based therapies, announced on January 2, 2024, the appointment of Ken Mobeck as its new Global Chief Financial Officer and Francois Dietsch as Global Chief Accounting Officer, both effective January 1, 2024. CEO Ryan Rhodes stated these appointments are crucial for aligning the organization with strategic growth initiatives, particularly expanding operational and commercial presence in the U.S., aiming to build shareholder value. This matters to investors as strong financial leadership is essential for executing growth strategies and ensuring transparent financial reporting, which can impact stock performance.

Why It Matters

New leadership in key financial roles can signal a company's commitment to strategic growth and improved financial oversight, potentially boosting investor confidence and operational efficiency.

Risk Assessment

Risk Level: low — The appointment of experienced financial officers is generally a positive or neutral event, reducing operational risk rather than increasing it.

Analyst Insight

Investors should monitor EDAP's progress in its U.S. market expansion and financial performance under the new leadership, as these appointments are intended to drive shareholder value.

Key Players & Entities

• EDAP TMS SA (company) — the company making the appointments
• Ken Mobeck (person) — appointed Global Chief Financial Officer
• Francois Dietsch (person) — appointed Global Chief Accounting Officer
• Ryan Rhodes (person) — Chief Executive Officer of EDAP

Forward-Looking Statements

• EDAP TMS SA will likely see increased focus on its U.S. market expansion. (EDAP TMS SA) — high confidence, target: 2024-12-31
• The company's financial reporting and investor relations may improve due to new leadership. (EDAP TMS SA) — medium confidence, target: 2024-06-30

FAQ

Filing Documents

• f6k_010224.htm (6-K) — 13KB
• logo.jpg (GRAPHIC) — 10KB
• 0001171843-24-000009.txt ( ) — 28KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 2, 2024 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer LYON, France, January 2, 2024 - EDAP TMS SA (Nasdaq: EDAP), ("EDAP"), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments are effective as of January 1, 2024. "Over the past year, we have continued to align our organization in support of our strategic growth initiatives to build shareholder value by focusing on expanding our operational and commercial presence in the U.S.," said Ryan Rhodes, Chief Executive Officer of EDAP. "Based on Ken's extensive experience in global finance, investor relations and operations, this appointment to Global Chief Financial Officer is consistent with our ongoing alignment and will enable EDAP to remain focused on executing our current growth strategy while also increasing our visibility amongst U.S. investors. Consistent with these changes, we also believe the timing is now ideal for establishing a formal, officer-level position for our global accounting function, and based upon Francois' impressive record of accomplishment and experience with EDAP, I am pleased that he will now serve as our Global Chief Accounting Officer." About EDAP TMS SA A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robot

Forward-Looking Statements

Forward-Looking Statements In addition to historical information, this press release contains forward-looking Act") or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as "believe," "can," "contemplate," "could," "plan," "intend," "is designed to," "may," "might," "potential," "objective," "target," "project," "predict," "forecast," "ambition," "guideline," "should," "will," "estimate," "expect" and "anticipate," or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. 1 Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement

Forward-looking statements speak only as of the date they are made. Other

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking such information forms a reasonable basis for such statements, such information may be limited or incomplete. Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.com Investor Contact John Fraunces LifeSci Advisors, LLC (917) 355-2395 jfraunces@lifesciadvisors.com 2

View Full Filing

View this 6-K filing on SEC EDGAR